BACKGROUND: Neutrophil elastase (NE) is a major secretory product from activated neutrophils and a major contributor to tissue destruction. However, little is known about the pathogenic contribution of NE to ulcerative colitis (UC). This study was designed to investigate the contribution of NE by measuring NE activity in plasma and colonic mucosal tissue from UC patients and a murine acute colitis model, and to elucidate the therapeutic effect of the NE-specific inhibitor ONO-5046. METHODS: The NE enzyme activities in plasma and colonic mucosal tissue from UC patients were directly measured using an enzyme-substrate reaction. Acute colitis was induced in mice by administration of 1.5% dextran sulfate sodium (DSS) for 5 days. DSS-induced colitis mice were then treated with ONO-5046 (50 mg/kg body weight) intraperitoneally twice a day. RESULTS: In UC patients, the NE enzyme activity was significantly elevated in both the plasma and colonic mucosal tissue compared with healthy controls. In DSS-induced colitis mice, the NE enzyme activity increased in parallel with the disease development. ONO-5046 showed therapeutic effects in DSS-treated mice by significantly reducing weight loss and histological score. ONO-5046 suppressed the NE enzyme activities in both plasma and culture supernatant of colonic mucosa from DSS-induced colitis mice. CONCLUSIONS: ONO-5046, a specific NE inhibitor, prevented the development of DSS-induced colitis in mice. NE therefore represents a promising target for the treatment of UC patients.
BACKGROUND: Neutrophil elastase (NE) is a major secretory product from activated neutrophils and a major contributor to tissue destruction. However, little is known about the pathogenic contribution of NE to ulcerative colitis (UC). This study was designed to investigate the contribution of NE by measuring NE activity in plasma and colonic mucosal tissue from UC patients and a murine acute colitis model, and to elucidate the therapeutic effect of the NE-specific inhibitor ONO-5046. METHODS: The NE enzyme activities in plasma and colonic mucosal tissue from UC patients were directly measured using an enzyme-substrate reaction. Acute colitis was induced in mice by administration of 1.5% dextran sulfate sodium (DSS) for 5 days. DSS-induced colitis mice were then treated with ONO-5046 (50 mg/kg body weight) intraperitoneally twice a day. RESULTS: In UC patients, the NE enzyme activity was significantly elevated in both the plasma and colonic mucosal tissue compared with healthy controls. In DSS-induced colitis mice, the NE enzyme activity increased in parallel with the disease development. ONO-5046 showed therapeutic effects in DSS-treated mice by significantly reducing weight loss and histological score. ONO-5046 suppressed the NE enzyme activities in both plasma and culture supernatant of colonic mucosa from DSS-induced colitis mice. CONCLUSIONS: ONO-5046, a specific NE inhibitor, prevented the development of DSS-induced colitis in mice. NE therefore represents a promising target for the treatment of UC patients.
Authors: B Siegmund; F Rieder; S Albrich; K Wolf; C Bidlingmaier; G S Firestein; D Boyle; H A Lehr; F Loher; G Hartmann; S Endres; A Eigler Journal: J Pharmacol Exp Ther Date: 2001-01 Impact factor: 4.030
Authors: N Yoshida; N Sugimoto; J Ochiai; Y Nakamura; H Ichikawa; Y Naito; T Yoshikawa Journal: Aliment Pharmacol Ther Date: 2002-04 Impact factor: 8.171
Authors: R William Vandivier; Valerie A Fadok; Peter R Hoffmann; Donna L Bratton; Churee Penvari; Kevin K Brown; Joseph D Brain; Frank J Accurso; Peter M Henson Journal: J Clin Invest Date: 2002-03 Impact factor: 14.808
Authors: O Saitoh; K Sugi; R Matsuse; K Uchida; H Matsumoto; K Nakagawa; K Takada; M Yoshizumi; I Hirata; K Katsu Journal: Am J Gastroenterol Date: 1995-03 Impact factor: 10.864
Authors: Xiangli Cui; Yu Jin; Anne B Hofseth; Edsel Pena; Joshua Habiger; Alexander Chumanevich; Deepak Poudyal; Mitzi Nagarkatti; Prakash S Nagarkatti; Udai P Singh; Lorne J Hofseth Journal: Cancer Prev Res (Phila) Date: 2010-03-23
Authors: Colm B Collins; Carol M Aherne; Stefan F Ehrentraut; Mark E Gerich; Eóin N McNamee; Martine C McManus; Matthew D P Lebsack; Paul Jedlicka; Tania Azam; Edwin F de Zoeten; Charles A Dinarello; Jesús Rivera-Nieves Journal: Inflamm Bowel Dis Date: 2013-08 Impact factor: 5.325
Authors: Ariel Munitz; Eric T Cole; Amanda Beichler; Katherine Groschwitz; Richard Ahrens; Kris Steinbrecher; Tara Willson; Xiaonan Han; Lee Denson; Marc E Rothenberg; Simon P Hogan Journal: Gastroenterology Date: 2010-04-14 Impact factor: 22.682
Authors: Rudolf Schicho; Mohammad Bashashati; Misha Bawa; Douglas McHugh; Dieter Saur; Huang-Ming Hu; Andreas Zimmer; Beat Lutz; Ken Mackie; Heather B Bradshaw; Donna-Marie McCafferty; Keith A Sharkey; Martin Storr Journal: Inflamm Bowel Dis Date: 2010-11-15 Impact factor: 5.325
Authors: Walter E Cromer; J Michael Mathis; Daniel N Granger; Ganta V Chaitanya; J Steven Alexander Journal: World J Gastroenterol Date: 2011-02-07 Impact factor: 5.742